Ipilimumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.

**Synonyms:** - Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody - BMS 734016 - BMS-734016 - BMS734016 - IPILIMUMAB - Ipilimumab Biosimilar CS1002 - MDX 010 - MDX-010 - MDX-010 - MDX-CTLA4 - MDX010 - Yervoy - ipilimumab